Ponzetto A, Figura N

Language: English
References: 5
Page: 1078-1080
PDF size: 104.69 Kb.

Text Extraction

Cruz-Ramon, et al. report on portal vein thrombosis (PVT) in patients with liver cirrhosis. We feel the necessity to avert and cure such underestimated and undertreated complication: PVT often proceeds to severe portal hypertension and bleeding, and correlates with lower life expectancy. A major problem is the wide disparity of treatments. We believe that a comment is warranted, as other possible mechanisms leading to PVT are often overlooked.. These mechanisms include neutrophilic infiltration, a cause of neutrophilic extracellular traps or NETosis, and anti-phospholipid syndrome (APS). Both conditions can be elicited by Helicobacter pylori (H. pylori) infection.

REFERENCES

1. Sharma AM, Zhu D, Henry Z. Portal vein thrombosis: When to treat and how? Vascular Medicine 2016; 21: 61-9.

2. Qi X, De Stefano V, Su C, Bai M, Guo X, Fan D. Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis. Medicine (Baltimore) 2015; 94: e496.

3. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-64.

4. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis. 9th Ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e419S-494S.

5. Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH1, Violi F; faculty of the 7th International Coagulation in Liver Disease. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 2018; 118(8): 1491-506.